Literature DB >> 20508896

High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting.

Rossella Marcucci1, Anna Maria Gori, Rita Paniccia, Betti Giusti, Serafina Valente, Cristina Giglioli, Piergiovanni Buonamici, David Antoniucci, Rosanna Abbate, Gian Franco Gensini.   

Abstract

There is some data available on the role of high on-treatment platelet reactivity by ADP whereas, as regards arachidonic acid or other agonists, there is no proof of the best cut-off for identifying populations with a different cardiovascular outcome by the construction of appropriate receiver-operator characteristics (ROC) curves. We enrolled 1,108 acute coronary syndrome patients undergoing percutaneous coronary intervention (PCI) with stent implantation and followed them up for 12 months. Platelet reactivity was assessed by light transmission aggregometry (LTA) using 10 microM ADP, 1 mM arachidonic acid (AA) and 2 microg/ml collagen. At a 12-month follow-up, we found 37 cardiovascular deaths (3.3%), 54 non-fatal myocardial infarctions (MI) (4.8%) and 154 target vessel revascularisations (TVR) (13.8%). ROC analysis demonstrated that 10 microM ADP LTA, 1 mM AA and 2 microg/ml collagen LTA were able to distinguish between patients with and without subsequent cardiovascular death and non-fatal MI (area under the curve for 10 microM ADP 0.63 (0.55-0.71), p<0.001; for 1 mM AA 0.68 (0.61-0.76), p<0.0001; for 2 microg/ml collagen 0.62 (0.52-0.73), p<0.0111), whereas no association was demonstrated with the occurrence of TVR. Ten microM ADP LTA>or=55%, 1 mM AA LTA>or=15% and 2 microg/ml collagen LTA>or=31% were identified as the optimal cut-off to predict cardiovascular death and non-fatal MI at 12-month follow-up. The contemporary platelet hyperreactivity to more than one agonist was associated with a higher risk of 12-month cardiovascular death and MI, whereas isolated platelet hyperreactivity to only one agonist had not a predictive value [10 microM ADP LTA>or=55% + 1 mM AA LTA>or=15%: odds ratio [OR]=3.6(2.4-6.1), p<0.0001; ADP LTA>or=55% + 1 mM AA LTA>or=15% + 2 microg/ml collagen LTA>or=31%: OR=4.7(2.9-7.7), p<0.0001]. In this prospective study on a large number of acute coronary syndrome patients undergoing stent implantation, we have found that high on-treatment platelet reactivity measured by LTA induced by more than one agonist--AA, ADP, collagen--is an independent risk factor for 12-month cardiovascular death and non-fatal MI. Isolated platelet hyperreactivity to only one agonist has not a predictive value for clinical recurrences.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20508896     DOI: 10.1160/TH10-01-0007

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  Persistent high on-treatment platelet reactivity in acute coronary syndrome.

Authors:  Donald R Lynch; Farooq H Khan; Dhananjay Vaidya; Marlene S Williams
Journal:  J Thromb Thrombolysis       Date:  2012-04       Impact factor: 2.300

2.  Effectiveness of antiplatelet therapy in atherosclerotic disease: comparing the ASA low-response prevalence in CVD, CAD and PAD.

Authors:  Saskia H Meves; Thomas Hummel; Heinz G Endres; Nora Mayböck; Andreas F C Kaiser; Kay D Schröder; Katja Rüdiger; Ursula Overbeck; Achim Mumme; Andreas Mügge; Horst Neubauer
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

3.  Genome-wide association study of platelet aggregation in African Americans.

Authors:  Rehan Qayyum; Lewis C Becker; Diane M Becker; Nauder Faraday; Lisa R Yanek; Suzanne M Leal; Chad Shaw; Rasika Mathias; Bhoom Suktitipat; Paul F Bray
Journal:  BMC Genet       Date:  2015-05-30       Impact factor: 2.797

4.  Lower loading dose of prasugrel compared with conventional loading doses of clopidogrel and prasugrel in korean patients undergoing elective coronary angiography: a randomized controlled study evaluating pharmacodynamic efficacy.

Authors:  Dong Hyun Lee; Moo Hyun Kim; Long Zhe Guo; Min Kyu Park; So Jeong Yi
Journal:  Korean Circ J       Date:  2014-11-25       Impact factor: 3.243

5.  High on-treatment platelet reactivity: risk factors and 5-year outcomes in patients with acute myocardial infarction.

Authors:  Martin Jakl; Robert Sevcik; Ilona Fatorova; Jan M Horacek; Radek Pudil
Journal:  Anatol J Cardiol       Date:  2016-10-05       Impact factor: 1.596

6.  The Influence of Inflammation on Fibrinogen Turnover and Redistribution of the Hemostatic Balance to a Prothrombotic State in High On-Treatment Platelet Reactivity-Dual Poor Responder (HTPR-DPR) Patients.

Authors:  Grzegorz Biolik; Dariusz Gajniak; Maciej Kubicz; Damian Ziaja; Krzysztof Ziaja; Wacław Kuczmik
Journal:  Mediators Inflamm       Date:  2019-07-17       Impact factor: 4.711

7.  Correlation between the CYP2C19 phenotype status and the results of three different platelet function tests in cardiovascular disease patients receiving antiplatelet therapy: an emphasis on newly introduced platelet function analyzer-200 P2Y test.

Authors:  Shuhua Li; Jae Lim Choi; Long Zhe Guo; Ri Young Goh; Bo Ram Kim; Kwang Sook Woo; Moo Hyun Kim; Jin Yeong Han
Journal:  Ann Lab Med       Date:  2016-01       Impact factor: 3.464

8.  Clopidogrel versus ticagrelor in the treatment of Chinese patients undergoing percutaneous coronary intervention: effects on platelet function assessed by platelet function tests and mean platelet volume.

Authors:  Yang Zhang; Rui Peng; Xiaojuan Li; Gaowa Cheng; Ximing Wang; Jinxing Yu; Muxing Hua; Xi Chen; Zhou Zhou
Journal:  Thromb J       Date:  2021-12-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.